Dr. Agnieszka Latosinska

Dr Agnieszka Latosinska

Biography

Agnieszka Latosinska, born in 1988 in Poland, received her PhD from the Charité-Universitätsmedizin Berlin, Germany in 2016.

Her research was advanced by the EU funded Marie Sklodowska Curie BCMolMed (Molecular Medicine for Bladder Cancer) EID Program (FP7-PEOPLE-2012-ITN-317450). As a part of this highly competitive project, she had the opportunity to share her time between academic and industrial laboratories, focusing on translational research. She succeeded in establishment of analytical workflows for proteome analysis covering every step from study design, sample preparation, data analysis, label-free/ label-based quantification, data interpretation and validation. Application of these methods led to improved understanding of the molecular mechanism underlying bladder cancer invasion followed by identification of the novel, biology driven therapeutic targets, as well as biomarkers. She participated in numerous international conferences, where she has received travel awards for the presented work. She was nominated and selected to join the prestigious Lindau meeting with Nobel Laureates in 2014.

Inspired by the need of translating the technological developments of basic science to clinically useful solutions, after the MSCA fellowship she continued her work at Mosaiques Diagnostics GmbH. She led collaborative projects in the area of urogenital cancers, funded by EC and BMBF (national funding body). In addition, she was involved in numerous translational projects, applying urinary and tissue proteomics to define biomarkers for chronic diseases, to better understand molecular mechanisms underlying diseases (in the context of genitourinary malignancies, and cardiovascular diseases) as well as to find potential therapeutic targets and drugs based on molecular profiling multi-omics data (in the context of genitourinary malignancies). Moreover, she has gained an extensive experience in grant writing and project management and reporting. Her two grant applications submitted for SME-2 call were awarded with the seal of excellence.

She was awarded with a Marie Sklodowska Curie Individual Fellowship (H2020-MSCA-IF-2017-800048) in 2018, where she has been further applying proteomics tools (in combination with other –omics data) to understand mechanisms associated with prostate cancer progression, and define molecularly driven therapeutic drug targets and therapeutic agents. The project was selected for assessment via the Innovation Radar EU Programme, highlighting the innovative potential of the proposed work and outcomes.

As a highlight, she contributed to more than 45 publications on clinical proteomics (including research and review articles, book chapters and others) that have been cited more than 650 times (H-index: 15). As a result of her outstanding achievements and expertise, she acted as a Guest Editor for the Special Issue in the leading journal Proteomics Clinical Applications, entitled “Clinical Proteomics on the Way Towards Implementation” (March 2019).

Her main research interest includes application of proteomics technologies and system biology approaches for defining biomarkers and investigating disease pathophysiology and drug targets for chronic diseases, with particular focus on understanding molecular mechanisms of fibrosis, especially the underlying collagen turnover.

CURRICULUM VITAE

Personal information

Family name, First name: Latosinska, Agnieszka

Date of birth: 01-05-1988

Nationality: Polish

Address: Rotenburger Str. 20, 30659 Hannover, Germany

Phone: +49(0)51155474430

E-mail: latosinska@mosaiques-diagnostics.com

Researcher unique identifier (ORCID): 0000-0001-8917-2412

Education

2013 - 2016 | Charité-Universitätsmedizin Berlin, Berlin, Germany

  • Degree: Doctor of clinical science, Doctor rerum medicinalium (summa cum laude)

  • Thesis topic: Optimizing methodologies for clinical proteomics

2010 - 2012 | Jagiellonian University, Cracow, Poland

  • Degree: Master of Science in Biotechnology Program, 2012

  • Thesis topic: Proteomic analysis of brain nuclear protein in pilocarpine model of temporal lobe epilepsy

2007 - 2010 | Jagiellonian University, Cracow, Poland

  • Degree: Bachelor of Science in Biotechnology Program, 2010

  • Thesis topic: Proteomic analysis of intrinsically disordered proteins

Work Experience

Senior scientists| MOSAIQUES DIAGNOSTICS GMBH, HANNOVER, GERMANY | April 2020 – date

  • Proteomics-based projects mainly in the area of cardiovascular diseases and also cancer || Analysis of high-resolution CE-MS and LC-MS/ MS data || Performed statistical analysis || Development of biomarker panels (machine learning algorithms) || Drug repurposing based on molecular data || Bioinformatics analysis || Dissemination || Grant submission || Reporting || Project management.

H2020 MSCA Fellow| pcaprotreat (IF programme) | MOSAIQUES DIAGNOSTICS GMBH, HANNOVER, GERMANY | April 2018 – March 2020

  • Marie Sklodowska Curie Actions, funded by the European Commission (H2020-MSCA-IF-2017-800048) || Integration of multi-omics (proteomics, peptidomics, transcriptomics) and multi-source data (tissue, urine, seminal plasma) || Statistical analysis || Systems Biology Workflows || Prediction of drugs/ compounds able to reverse disease signature || Annotation and selection of potential drug candidates, and drug targets || Multi-disciplinary training.

Post-doctoral Fellow | Mosaiques Diagnostics GmbH, Hannover, Germany | October 2017 – March 2018

  • Proteomics-based projects || Analysis of high-resolution CE-MS and LC-MS/ MS data || Performed statistical analysis || Development of biomarker panels (machine learning algorithms) || Dissemination || Grant submission || Reporting || Project management.

Research internship | Systems Biology Ireland (SBI) - University College Dublin, Dublin, Ireland | July 2017 – September 2017

  • Extensive training in Systems Biology approaches.

Post-Doctoral Fellow | Mosaiques Diagnostics GmbH, Hannover, Germany | January 2016 – December 2016 & February 2017 – July 2017

  • Proteomics-based project in the area of bladder, prostate cancer and cardiovascular diseases || Analysis of high-resolution LC-MS/MS data || Critically assessed the quality of LC-MS/MS results || Analysis of high-resolution CE-MS data || Performed statistical analysis || Prepared and disseminated promotional materials to different target groups || Reporting || Grant writing || Project management.

PhD Researcher, MSCA fellow | Bcmolmed (EID programme) | Biomedical Research Foundation of the Academy of Athens, Athens, Greece | January 2013- January 2016

  • Optimized and developed sample preparation protocols for LC-MS/MS analysis (tissue, cells, urine) || Established protocols for subcellular fractionation (ER/Golgi, Membrane, Nuclei, Secretome) || Prepared samples for down-stream proteomics analysis (SDS-PAGE, 2DE, LC-MS/MS) || Assessed and applied software’s for processing and quantification of LC-MS/MS data || Analysed LC-MS/MS data (Proteome Discoverer, Trans-Proteomic Pipeline) || Performed proteomics data functional annotation, pathway and network analysis || Interpreted and prioritized proteomics findings || Investigated mechanisms associated with bladder cancer invasion || Performed cell culture and molecular biology assays || Solved technical problems creatively.

Editorial, Reviewer Activities

Prizes and Awards

  • Seal of Excellence Certificate for the project proposal 880256 entitled “An innovative Service to identify Molecularly-driven therapeutic agents and drug targets in Oncology” submitted under the Horizon 2020’s SME instrument phase 2 call (June 2019)

  • Seal of Excellence Certificate for the project proposal entitled “Biomarker Guided Prostate Cancer Management” submitted under the Horizon 2020’s SME instrument phase 2 (January 2019)

  • BJU International Prize for the best academic paper for Presentation entitled “A Urinary Peptide Biomarker Panel to Identify Significant Prostate Cancer” (BAUS Annual Meeting 2016, Liverpool, UK)

  • Travel award for the poster presentation entitled “Identification of proteins involved in invasion of bladder cancer using cell line models” (22nd Meeting of EAU Section of Urological Research, Glasgow, UK)

  • 64th Lindau Nobel Laureate Meeting on Physiology or Medicine (Lindau, Germany, 2014)

Funding received so far

  • Eurostars project 2020-2023: ReDiRECt (E! 113726)

  • MSCA Individual Fellowship 2018-2020: PCaProTreat MSCA-IF-EF-SE EID-ITN (800048)

  • Eurostars project 2017-2019: BioGuidePCa (E!11023)

Bibliography

H-index: 15; Sum of Times Cited: 670

  1. He T, Mischak M, Clark AL, Campbell RT, Delles C, Díez J, Filipatos G, Mebazaa A, McMurray JJV, González A, Raad J, Stroggilos R, Bosselmann HS, Campbell A, Kerr S, Jackson CE, Cannon JA, Schou M, Girerd N, Rossignol P, McConnachie A, Rossing K, Schanstra JP, Zannad F, Vlahou A, Mullen W, Jankowski V, Mischak H, Zhang Z, Staessen JA, Latosinska A. Urinary peptides in heart failure: a link to molecular pathophysiology. Eur J Heart Fail. 2021 (in press).

  2. Mokou M, Frantzi M, Mischak H, Vlahou A, Latosinska A. Developing novel drug candidates and repurposed drugs for prostate cancer based on molecular profiles. Curr Med Chem. 2021 (in press).

  3. He T, Zhang Z, Staessen JA, Mischak H, Latosinska A, Beige J. Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology. Am J Hypertens. 2021 Apr 2:hpaa201. doi: 10.1093/ajh/hpaa201. Epub ahead of print. PMID: 33821948.

  4. Mavrogeorgis E, Mischak H, Beige J, Latosinska A, Siwy J. Understanding glomerular diseases through proteomics. Expert Rev Proteomics. 2021 Apr 8:1-21. doi: 10.1080/14789450.2021.1908893. Epub ahead of print. PMID: 33779448.

  5. Siwy J, Wendt R, Albalat A, He T, Mischak H, Mullen W, Latosinska A, Lübbert C, Kalbitz S, Mebazaa A, Peters B, Stegmayr B, Spasovski G, Wiech T, Staessen JA, Wolf J, Beige J. Critical COVID-19 represents an endothelial disease with high similarity to kidney disease on the molecular level. medRxiv 2021.02.22. doi: https://doi.org/10.1101/2021.02.22.21252207

  6. He T, Melgarejo JD, Clark AL, Yu YL, Thijs L, Díez J, López B, González A, Cleland JG, Schanstra JP, Vlahou A, Latosinska A, Mischak H, Staessen JA, Zhang ZY, Jankowski V. Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure. Clin Transl Med. 2021 Jan;11(1):e267. doi: 10.1002/ctm2.267. PMID: 33463057; PMCID: PMC7803349.

  7. Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A. Drug repurposing in oncology. Lancet Oncol. 2020 Dec;21(12):e543. doi: 10.1016/S1470-2045(20)30610-0. PMID: 33271100.

  8. Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Bamias A, Hoffmann MJ, Mischak H, Vlahou A. A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. Cancers (Basel). 2020 Nov 26;12(12):3519. doi: 10.3390/cancers12123519. PMID: 33255925; PMCID: PMC7759896.

  9. Bannaga AS, Metzger J, Kyrou I, Voigtländer T, Book T, Melgarejo J, Latosinska A, Pejchinovski M, Staessen JA, Mischak H, Manns MP, Arasaradnam RP. Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis-A multicentre study. EBioMedicine. 2020 Dec;62:103083. doi: 10.1016/j.ebiom.2020.103083. Epub 2020 Nov 5. PMID: 33160210; PMCID: PMC7648178.

  10. Wendt R, He T, Latosinska A, Siwy J, Mischak H, Beige J. Proteomic characterization of obesity-related nephropathy. Clin Kidney J. 2020 Apr 15;13(4):684-692. doi: 10.1093/ckj/sfaa016. PMID: 32905225; PMCID: PMC7467596.

  11. Frantzi M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A. Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics (Basel). 2020 Aug 31;10(9):658. doi: 10.3390/diagnostics10090658. PMID: 32878288; PMCID: PMC7555799.

  12. Latosinska A, Davalieva K, Makridakis M, Mullen W, Schanstra JP, Vlahou A, Mischak H, Frantzi M. Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. Diagnostics (Basel). 2020 Aug 31;10(9):655. doi: 10.3390/diagnostics10090655. PMID: 32878211; PMCID: PMC7554904.

  13. Latosinska A, Siwy J, Faguer S, Beige J, Mischak H, Schanstra JP. Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. Proteomics Clin Appl. 2021 Jan;15(1):e2000027. doi: 10.1002/prca.202000027. Epub 2020 Aug 16. PMID: 32710812.

  14. Campbell RT, Jasilek A, Mischak H, Nkuipou-Kenfack E, Latosinska A, Welsh PI, Jackson CE, Cannon J, McConnachie A, Delles C, McMurray JJV. The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Fail. 2020 Aug;7(4):1595-1604. doi: 10.1002/ehf2.12708. Epub 2020 May 8. PMID: 32383555; PMCID: PMC7373887.

  15. Nkuipou-Kenfack E, Latosinska A, Yang WY, Fournier MC, Blet A, Mujaj B, Thijs L, Feliot E, Gayat E, Mischak H, Staessen JA, Mebazaa A, Zhang ZY; French and European Outcome Registry in Intensive Care Unit Investigators. A novel urinary biomarker predicts 1-year mortality after discharge from intensive care. Crit Care. 2020 Jan 9;24(1):10. doi: 10.1186/s13054-019-2686-0. PMID: 31918764; PMCID: PMC6953276.

  16. Voigtländer T, Metzger J, Husi H, Kirstein MM, Pejchinovski M, Latosinska A, Frantzi M, Mullen W, Book T, Mischak H, Manns MP. Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma. J Biomed Sci. 2020 Jan 3;27(1):13. doi: 10.1186/s12929-019-0599-5. PMID: 31900160; PMCID: PMC6941325.

  17. Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V. Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors. Sci Rep. 2019 Sep 3;9(1):12864. doi: 10.1038/s41598-019-49304-9. Erratum for: Sci Rep. 2018 Mar 27;8(1):5227. PMID: 31477787; PMCID: PMC6718396.

  18. Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Lazaris AC, Makrythanasis P, Ntoumas K, Mischak H, Zoidakis J, Vlahou A. Proteome-based classification of Nonmuscle Invasive Bladder Cancer. Int J Cancer. 2020 Jan 1;146(1):281-294. doi: 10.1002/ijc.32556. Epub 2019 Jul 26. PMID: 31286493.

  19. Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J. CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16. PMID: 31092909; PMCID: PMC6738044.

  20. Schanstra JP, Luong TT, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, Alesutan I, Boehme B, Schelski N, Von Lewinski D, Mullen W, Nicklin S, Delles C, Feuillet G, Denis C, Lang F, Pieske B, Bascands JL, Mischak H, Saulnier-Blache JS, Voelkl J, Vlahou A, Klein J. Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. JCI Insight. 2019 May 16;4(10):e125638. doi: 10.1172/jci.insight.125638. PMID: 31092728; PMCID: PMC6542631.

  21. Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. Electrophoresis. 2019 Sep;40(18-19):2294-2308. doi: 10.1002/elps.201900091. Epub 2019 May 14. PMID: 31054149.

  22. Frantzi M, Mischak H, Latosinska A. Clinical Proteomics on the Path Toward Implementation: First Promises Delivered. Proteomics Clin Appl. 2019 Mar;13(2):e1800094. doi: 10.1002/prca.201800094. PMID: 30767399.

  23. Frantzi M, Latosinska A, Mischak H. Proteomics in Drug Development: The Dawn of a New Era? Proteomics Clin Appl. 2019 Mar;13(2):e1800087. doi: 10.1002/prca.201800087. Epub 2019 Feb 25. PMID: 30724014.

  24. Frantzi M, Latosinska A, Belczacka I, Mischak H. Urinary proteomic biomarkers in oncology: ready for implementation? Expert Rev Proteomics. 2019 Jan;16(1):49-63. doi: 10.1080/14789450.2018.1547193. Epub 2018 Nov 15. PMID: 30412678.

  25. Latosinska A, Frantzi M, Merseburger AS, Mischak H. Promise and Implementation of Proteomic Prostate Cancer Biomarkers. Diagnostics (Basel). 2018 Aug 29;8(3):57. doi: 10.3390/diagnostics8030057. PMID: 30158500; PMCID: PMC6174350.

  26. Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M. Proteomics biomarkers for solid tumors: Current status and future prospects. Mass Spectrom Rev. 2019 Jan;38(1):49-78. doi: 10.1002/mas.21572. Epub 2018 Jun 11. PMID: 29889308.

  27. Frantzi M, Latosinska A, Kontostathi G, Mischak H. Clinical Proteomics: Closing the Gap from Discovery to Implementation. Proteomics. 2018 Jul;18(14):e1700463. doi: 10.1002/pmic.201700463. Epub 2018 Jul 8. PMID: 29785737.

  28. Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A. Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. J Transl Med. 2018 Apr 17;16(1):104. doi: 10.1186/s12967-018-1476-9. PMID: 29665821; PMCID: PMC5905170.

  29. Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V. Urinary CE-MS peptide marker pattern for detection of solid tumors. Sci Rep. 2018 Mar 27;8(1):5227. doi: 10.1038/s41598-018-23585-y. Erratum in: Sci Rep. 2019 Sep 3;9(1):12864. PMID: 29588543; PMCID: PMC5869723.

  30. Frantzi M¶, Latosinska A¶, Mischak H. Urinary biomarkers in the management of prostate cancer. Editorial, 2018 July, https://oncology.medicinematters.com/

  31. Belczacka I, Latosinska A, Frantzi M, Mischak H. Urinary CE-MS Peptide Marker Pattern for Detection of Solid Tumors, "Beyond the Abstract". 2018 May, https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/103984-urinary-ce-ms-peptide-marker-pattern-for-detection-of-solid-tumors-beyond-the-abstract.html

  32. Frantzi M, Latosinska A, Akand M, Merseburger AS. Chapter 21. Application of Omics and Systems Medicine in Bladder Cancer. In: Vlahou A, Mischak H, Zoidakis J, Magni F, ed. Integration of Omics Approaches and Systems Biology for Clinical Applications. John Wiley & Sons, Inc. 2018: 347-360. doi: 10.1002/9781119183952.ch21.

  33. Latosinska A, Vlahou A, Makridakis M. Chapter 8. Tissue Proteomics. In: Vlahou A, Mischak H, Zoidakis J, Magni F, ed. Integration of Omics Approaches and Systems Biology for Clinical Applications. John Wiley & Sons, Inc. 2018: 129-155. doi: 10.1002/9781119183952.ch8.

  34. Marx D, Metzger J, Pejchinovski M, Gil RB, Frantzi M, Latosinska A, Belczacka I, Heinzmann SS, Husi H, Zoidakis J, Klingele M, Herget-Rosenthal S. Proteomics and Metabolomics for AKI Diagnosis. Semin Nephrol. 2018 Jan;38(1):63-87. doi: 10.1016/j.semnephrol.2017.09.007. PMID: 29291763.

  35. Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A. Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. PMID: 29050215; PMCID: PMC5642490.

  36. Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. Proteomics Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700074. Epub 2017 Oct 25. PMID: 28980455.

  37. Latosinska A, Hulko M, Speidel R, Mischak H, Storr M, Krause B. Removal of Cell-Activating Substances Using Dialyzers With Various Permeability Profiles. Artif Organs. 2018 Jan;42(1):78-87. doi: 10.1111/aor.12952. Epub 2017 Jul 26. PMID: 28744941.

  38. Siebert S, Porter D, Paterson C, Hampson R, Gaya D, Latosinska A, Mischak H, Schanstra J, Mullen W, McInnes I. Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Sci Rep. 2017 Jan 16;7:40473. doi: 10.1038/srep40473. PMID: 28091549; PMCID: PMC5320079.

  39. Frantzi M, Klimou Z, Makridakis M, Zoidakis J, Latosinska A, Borràs DM, Janssen B, Giannopoulou I, Lygirou V, Lazaris AC, Anagnou NP, Mischak H, Roubelakis MG, Vlahou A. Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models. Oncotarget. 2016 Oct 25;7(43):70750-70768. doi: 10.18632/oncotarget.12218. PMID: 27683119; PMCID: PMC5342587.

  40. Latosinska A, Makridakis M, Frantzi M, Borràs DM, Janssen B, Mullen W, Zoidakis J, Merseburger AS, Jankowski V, Mischak H, Vlahou A. Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. Sci Rep. 2016 May 11;6:25619. doi: 10.1038/srep25619. PMID: 27167498; PMCID: PMC4863247.

  41. Chatziharalambous D, Lygirou V, Latosinska A, Stravodimos K, Vlahou A, Jankowski V, Zoidakis J. Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation. PLoS One. 2016 Feb 18;11(2):e0149471. doi: 10.1371/journal.pone.0149471. PMID: 26889680; PMCID: PMC4758723.

  42. Jankowska U, Latosinska A, Skupien-Rabian B, Swiderska B, Dziedzicka-Wasylewska M, Kedracka-Krok S. Optimized procedure of extraction, purification and proteomic analysis of nuclear proteins from mouse brain. J Neurosci Methods. 2016 Mar 1;261:1-9. doi: 10.1016/j.jneumeth.2015.12.002. Epub 2015 Dec 14. PMID: 26698226.

  43. Frantzi M, Latosinska A, Merseburger AS, Mischak H. Recent progress in urinary proteome analysis for prostate cancer diagnosis and management. Expert Rev Mol Diagn. 2015;15(12):1539-54. doi: 10.1586/14737159.2015.1104248. Epub 2015 Oct 22. PMID: 26491818.

  44. Latosinska A, Vougas K, Makridakis M, Klein J, Mullen W, Abbas M, Stravodimos K, Katafigiotis I, Merseburger AS, Zoidakis J, Mischak H, Vlahou A, Jankowski V. Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis. PLoS One. 2015 Sep 2;10(9):e0137048. doi: 10.1371/journal.pone.0137048. Erratum in: PLoS One. 2015;10(10):e0139268. PMID: 26331617; PMCID: PMC4557910.

  45. Filip S, Vougas K, Zoidakis J, Latosinska A, Mullen W, Spasovski G, Mischak H, Vlahou A, Jankowski J. Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine. PLoS One. 2015 Jul 24;10(7):e0133773. doi: 10.1371/journal.pone.0133773. PMID: 26208298; PMCID: PMC4514849.

  46. Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 2015 Jun;12(6):317-30. doi: 10.1038/nrurol.2015.100. Epub 2015 May 26. PMID: 26032553.

  47. Latosinska A, Frantzi M, Mullen W, Vlahou A, Makridakis M. Targeting the proteome of cellular fractions: focus on secreted proteins. Methods Mol Biol. 2015;1243:29-41. doi: 10.1007/978-1-4939-1872-0_2. PMID: 25384738.

  48. Latosinska A, Frantzi M, Flühe L, and Mischak H. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery for bladder cancer, "Beyond the Abstract". 2014 Aug, https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/73998-clinical-applications-of-capillary-electrophoresis-coupled-to-mass-spectrometry-in-biomarker-discovery-for-bladder-cancer-beyond-the-abstract-by-agnieszka-latosinska-maria-frantzi-leif-fluehe-and-harald-mischak.html

  49. Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014 Mar 29;3(1):7. doi: 10.1186/2001-1326-3-7. PMID: 24679154; PMCID: PMC3994249.

  50. Latosinska A, Frantzi M, Vlahou A, Mischak H. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer. Proteomics Clin Appl. 2013 Dec;7(11-12):779-93. doi: 10.1002/prca.201300038. PMID: 23970371.